IntraBio, Inc.

IB1001-304 is the first pivotal clinical trial conducted specifically for CACNA1A-related disorders , for which there are currently no approved therapies anywhere in the world. Recruitment for IB1001-304 has commenced; IntraBio anticipates the study will over-enroll and complete recruitment in October 2026. CACNA1A-related disorders have an incidence of approximately 1 in 11,700, corresponding to more than 30,000 individuals in the United States alone and an estimated 690,000 worldwide. IB1001-304 uses the same pivotal trial design that supported FDA approval and European Commission authorization of levacetylleucine (AQNEURSA®) in Niemann-Pick disease type C. AUSTIN, Texas--(BUSINESS WIRE)--IntraBio Inc., a global biopharmaceutical company developing and commercializing therapies for rare and common neurological diseases, today announced that its pivotal Phase III IB1001-304 trial evaluating levacetylleucine in individuals with CACNA1A-related disorders is enrolling. The company anticipates the study will over-enroll and complete recruitment in October 2026, with the trial designed to take 6-months to complete. IB1001-304 is the first pivotal clinical trial conducted specifically for CACNA1A-related disorders. The study uses the same design as the pivotal trial that supported U.S. FDA approval and European Commission authorization of levacetylleucine (AQNEURSA®) for the neurological manifestations of Niemann-Pick disease type C (NPC), and that supported IntraBio’s positive Phase III study in Ataxia-Telangiectasia (A-T). The supplemental New Drug Application for A-T is currently under FDA Priority Review, with a PDUFA target action date of September 19, 2026. “This trial marks a pivotal milestone for the CACNA1A community,” said Lisa Manaster, Co-Founder and President of the CACNA1A Foundation. “As the mother of a daughter living with a CACNA1A-related disorder, I know firsthand what it means to have real hope that we are moving closer to having an approved, safe, and effective treatment. Given the urgent unmet need our families face, we look forward to continuing to collaborate with IntraBio to help ensure this novel treatment is rapidly made available to patients in our community.” CACNA1A-related disorders refer to a group of rare, inherited neurological conditions. Despite the severity and lifelong course of these conditions, there are currently no approved therapies indicated for CACNA1A-related disorders anywhere in the world. The estimated incidence of CACNA1A-related disorders is approximately 1 in 11,700, corresponding to approximately 30,000 individuals in the United States alone and an estimated 690,000 worldwide. About IB1001-304 IB1001-304 is a multinational, randomized, double-blind, placebo-controlled crossover Phase III clinical trial evaluating levacetylleucine in individuals aged four years and older with genetically confirmed CACNA1A-related disorders. The trial is being conducted at multinational sites in Austria, Germany, Greece, Italy, Switzerland, the United Kingdom and the United States. Further information about IB1001-304, including participating locations and eligibility requirements, is available at ClinicalTrials.gov under study NCT07221292. The study is registered on ClinicalTrials.gov as NCT07221292 and under EU CT Number 2025-523828-51. Levacetylleucine is investigational for the treatment of CACNA1A-related disorders and has not been approved by the FDA, MHRA, European Commission, Swissmedic or any other regulatory authority for this indication. About CACNA1A-Related Disorders CACNA1A-related disorders are rare, inherited neurological conditions caused by pathogenic variants in the CACNA1A gene, which plays a central role in calcium-channel function within the nervous system. Symptoms can begin in infancy, childhood or adulthood. The estimated incidence of CACNA1A-related disorders is approximately one in 11,700. There are currently no approved therapies indicated for CACNA1A-related disorders. About AQNEURSA® (levacetylleucine) U.S. Indication AQNEURSA® (levacetylleucine) is indicated in the United States for the treatment of neurological manifestations of Niemann-Pick disease type C (NPC) in adults and pediatric patients weighing at least 15 kg. U.S. IMPORTANT SAFETY INFORMATION Embryo-Fetal Toxicity Based on findings from animal reproduction studies, AQNEURSA may cause embryo-fetal harm when administered during pregnancy. The decision to continue or discontinue AQNEURSA during pregnancy should consider the patient’s clinical need, the potential drug-related risks to the fetus, and the potential adverse outcomes from untreated maternal disease. Pregnancy and Lactation: For females of reproductive potential, confirm the patient is not pregnant prior to initiating treatment. Advise use of effective contraception during treatment and for 7 days after the last dose if AQNEURSA is discontinued. There are no data on the presence of levacetylleucine or its metabolites in human or animal milk; the developmental and health benefits of breastfeeding should be weighed against clinical need and potential risks to the infant. Adverse Reactions The most common adverse reactions (incidence ≥5% and greater than placebo) are abdominal pain, dysphagia, upper respiratory tract infections, and vomiting. Drug Interactions Avoid concomitant use of AQNEURSA with N-acetyl-DL-leucine or N-acetyl-D-leucine. The D-enantiomer competes with levacetylleucine for monocarboxylate transporter uptake, potentially reducing efficacy. Monitor more frequently for P-gp substrate-related adverse reactions when used concomitantly with AQNEURSA, as AQNEURSA inhibits P-gp; the clinical significance of this finding has not been fully characterized. To report SUSPECTED ADVERSE REACTIONS, contact IntraBio Inc. at 1-833-306-9677 or FDA at 1-800-FDA-1088 or visit . Please see Full U.S. Prescribing Information for AQNEURSA at aqneursahcp.com . EU (EMA) Indication AQNEURSA® is authorized in the European Union for the treatment of neurological manifestations of Niemann-Pick disease type C, in combination with miglustat or as a monotherapy in patients where miglustat is not tolerated, in adults and children aged 6 years and older and weighing at least 20 kg. See EMA Indication and Important Safety Information: About IntraBio IntraBio Inc. is a global biopharmaceutical company headquartered in Austin, Texas, focused on developing and commercializing targeted therapies for rare and common neurological, neurodevelopmental and mitochondrial diseases. IntraBio’s platform technologies are built on decades of scientific research and collaboration with leading institutions worldwide. Forward-Looking Statements This press release contains forward-looking statements, including statements regarding the anticipated pace and completion of enrollment in IB1001-304, the expected timing on which the study will close to further participants, the potential of levacetylleucine in CACNA1A-related disorders and other indications, and the anticipated timing of regulatory action. These statements are based on IntraBio’s current expectations and are subject to risks and uncertainties, including the pace of patient identification and screening, site activation timelines, and regulatory and clinical developments. Actual results may differ materially. IntraBio undertakes no obligation to update any forward-looking statement except as required by law. Contacts MEDIA & INVESTOR CONTACT Cass Fields Vice President, External Affairs ccfields@intrabio.com

AUSTIN, Texas--(BUSINESS WIRE)--The last paragraph in the release after the boilerplate has been removed. The updated release reads: INTRABIO ANNOUNCES PUBLICATION OF NEW RESEARCH SHOWING A DIRECT, BIDIRECTIONAL EFFECT ON LYSOSOMAL FUNCTION WITH LEVACETYLLEUCINE IntraBio today announced the publication of new research in PLOS ONE describing a newly identified way that levacetylleucine, the active ingredient in AQNEURSA®, acts directly on cellular lysosomal function. ezstandalone.cmd.push(function () { ezstandalone.showAds(131); }); The study, conducted by researchers at the University of Oxford, examined the drug's effect on Transcription Factor EB (TFEB), the master transcriptional regulator of lysosomal biogenesis and autophagy - the cellular systems responsible for clearing damaged proteins and lipids. Uniquely, a biphasic action of levacetylleucine on TFEB activity was identified, whereby levacetylleucine normalizes TFEB, activating its translocation in disease models when there is a deficiency, but also downregulating TFEB in models where it is overstimulated, thereby maintaining cellular homeostasis. This biphasic action is essential for a therapeutic effect and to ensure TFEB is not persistently overexpressed. The effect was also shown to be stereospecific and rapid in onset, appearing within approximately one hour. Only the purified L-enantiomer (levacetylleucine) was active; the D-enantiomer and the racemic mixture produced no effect, reinforcing the distinct pharmacology of the purified L-enantiomer used in AQNEURSA. Levacetyllecuine has been previously identified to have polypharmacolohical effects, with direct action on other cellular organelles such as the mitochondria, where it normalizes energy metabolism (cellular energy production). These novel findings provide the first evidence that levacetylleucine directly modulates lysosomal function. As TFEB dysregulation is implicated in a range of neurodegenerative and neurodevelopmental conditions, these findings provide further evidence of the potential applicability of levacetylleucine as a broad treatment for rare and common neurological conditions. “We have not previously observed a mechanism that regulates TFEB in this bidirectional, homeostasis-restoring manner,” said Professor Antony Galione, FRS FMedSci, senior and corresponding author and Professor of Pharmacology at the University of Oxford. “Rather than simply activating or inhibiting the pathway, levacetylleucine appears to recalibrate lysosomal activity according to the state of the cell to match its needs – in effect, acting as a molecular thermostat. These findings are remarkable and may have important implications for diseases characterized by lysosomal and mitochondrial dysfunction.” The full publication, “N-acetyl-L-leucine normalizes Transcription Factor EB activity by stereospecific bidirectional modulation in a HeLa cell model of Niemann-Pick disease type C,” can be accessed here: ABOUT INTRABIO IntraBio Inc. is a global biopharmaceutical company headquartered in Austin, Texas, focused on developing and commercializing targeted therapies for rare and common neurological, neurodevelopmental, and mitochondrial diseases. IntraBio’s platform technologies are built on decades of scientific research and collaboration with leading institutions worldwide, including the University of Oxford and the University of Munich. Contacts MEDIA & INVESTOR CONTACT Cass Fields | Vice President, External Affairs & Marketing ccfields@intrabio.com intrabio.com

NEWARK, Del. 特拉华州纽瓦克, ，June 25, 2026 2026年6月25日/PRNewswire/ -- According to a recent study by Future Market Insights (FMI), the global /美通社/ -- 根据未来市场洞察（FMI）最近的一项研究，全球Rare Neurological Disease Treatment Market 罕见神经系统疾病治疗市场is entering a high-value growth phase, driven by accelerated orphan drug approvals, expanding genomic diagnostics, and improved access to specialist care pathways. The market is projected to grow from 正进入高价值增长阶段，这得益于孤儿药审批加速、基因组诊断范围扩大以及专科诊疗路径可及性的提升。预计市场将从USD 21.5 billion in 2026 to USD 43.7 billion by 2036 从2026年的215亿美元增长到2036年的437亿美元, registering a ，记录了一个CAGR of 7.4% 复合年增长率7.4%during the forecast period. 在预测期内。The market is evolving as treatment for ultra-rare neurological and neuromuscular disorders shifts from symptom management toward targeted therapies, including gene therapies, antisense drugs, biologics, and disease-modifying small molecules. Increased early diagnosis through genetic testing is improving patient identification before irreversible neurological decline, expanding treatment eligibility across previously underserved patient populations.. 随着超罕见神经系统和神经肌肉疾病的治疗从症状管理转向靶向疗法（包括基因疗法、反义药物、生物制剂和疾病修饰小分子），市场正在不断演变。通过基因检测提高早期诊断率，有助于在不可逆的神经功能衰退之前识别患者，从而扩大此前服务不足的患者群体的治疗适用范围。Demand growth is being supported by regulatory fast-track pathways for orphan drugs, greater reimbursement focus on high-value specialty therapies, and rising clinical adoption of precision medicines for diseases such as amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), Duchenne muscular dystrophy (DMD), Niemann-Pick disease type C (NPC), and metachromatic leukodystrophy (MLD).. 孤儿药的监管快速通道、对高价值专科疗法报销的更大关注，以及针对肌萎缩侧索硬化症（ALS）、脊髓性肌萎缩症（SMA）、杜氏肌营养不良症（DMD）、C型尼曼-匹克病（NPC）和异染性脑白质营养不良（MLD）等疾病的精准医疗在临床上的日益普及，正在推动需求增长。As high-cost specialty therapies gain traction, pharmaceutical companies with strong clinical evidence, specialist distribution networks, and long-term patient monitoring capabilities are expected to secure long-term competitive advantage. 随着高成本专科疗法日益普及，拥有强大临床证据、专业分销网络以及长期患者监测能力的制药公司有望获得长期的竞争优势。Get detailed market forecasts, competitive benchmarking, and pricing trends: 获取详细的市场预测、竞争基准分析和价格趋势：https://www.futuremarketinsights.com/reports/sample/rep-gb-6445 https://www.futuremarketinsights.com/reports/sample/rep-gb-6445Market Overview 市场概览The rare neurological disease treatment market has evolved into one of the most strategically important segments within orphan pharmaceuticals. Market value is increasingly driven by precision therapies targeting genetically defined patient populations, where diagnosis timing, treatment efficacy, and reimbursement access directly influence commercial success.. 罕见神经系统疾病治疗市场已发展成为孤儿药领域中最具战略重要性的细分市场之一。市场价值日益由针对基因定义患者群体的精准疗法所驱动，其中诊断时机、治疗疗效以及报销准入直接决定商业成功。The market is expected to rise from 预计市场将上涨USD 20.0 billion in 2025 2025年达200亿美元to 到USD 43.7 billion by 2036 到2036年达到437亿美元, supported by broader treatment availability and increasing integration of genomic diagnostics into neurology care pathways. ，这得益于更广泛的治疗可及性，以及基因组诊断在神经科诊疗路径中的日益整合。Unlike traditional neurological treatments, therapies in this segment often require specialist administration, intensive monitoring, and payer justification. Consequently, market leadership increasingly depends on companies capable of combining clinical innovation with evidence generation and specialist support infrastructure.. 与传统神经学治疗不同，该领域的疗法通常需要具备专业资质的人员给药、强化监测以及向支付方提供合理性证明。因此，市场领导地位日益依赖于那些能够将临床创新与证据生成及专科支持基础设施相结合的企业。Key Growth Drivers 关键增长驱动因素A major growth catalyst is the expansion of 一个主要的增长催化剂是扩展genetic and biomarker-based diagnosis 基于基因和生物标志物的诊断, enabling earlier identification of rare neurological disorders. Early diagnosis significantly improves treatment outcomes, especially for diseases where intervention before severe degeneration is critical. ，从而实现更早地识别罕见神经系统疾病。早期诊断可显著改善治疗效果，对于那些在严重退化发生前进行干预至关重要的疾病而言尤其如此。Regulatory support for orphan therapies is another major driver. Faster review pathways for rare diseases and pediatric neurological disorders are accelerating approvals of innovative therapies across major healthcare markets. 对孤儿药疗法的监管支持是另一个主要驱动因素。针对罕见病和儿童神经系统疾病的快速审评通道，正在加速创新疗法在主要医疗市场的获批进程。The continued expansion of newborn screening programs is also increasing demand for early-stage treatment interventions, particularly for neuromuscular and genetic disorders. 新生儿筛查项目的持续扩展也增加了对早期治疗干预的需求，尤其是针对神经肌肉疾病和遗传性疾病。Commercial uptake of new therapies is strengthening market momentum. Recently approved therapies for ultra-rare diseases continue to expand the addressable patient base and create long-term revenue opportunities for treatment developers. 新疗法的商业化应用正在增强市场动力。最近获批的超罕见病疗法继续扩大可治疗患者群体，并为治疗开发商创造长期收入机会。Technology & Innovation Trends 技术与创新趋势Innovation in the rare neurological disease treatment market is centered around 罕见神经系统疾病治疗市场的创新集中在precision therapeutics, gene therapy delivery, and patient-centric formulations 精准治疗、基因递送以及以患者为中心的制剂. 。Gene therapies and antisense oligonucleotide platforms are transforming treatment approaches for genetically defined diseases by addressing underlying disease mechanisms rather than symptoms alone. 基因疗法和反义寡核苷酸平台正在通过针对潜在的疾病机制，而不仅仅是症状，来改变遗传性定义疾病的治疗方法。Oral formulations remain dominant and are projected to account for 口服制剂仍占主导地位，预计将占72.0% of route-of-administration share in 2026 2026年给药途径占比为72.0%, reflecting strong preference for chronic therapies that reduce hospital dependence and improve treatment adherence. ，反映出对能够减少医院依赖并提高治疗依从性的慢性疗法的强烈偏好。Advances in biomarker-driven patient selection are also improving clinical trial efficiency and reimbursement acceptance by demonstrating measurable treatment benefits. 生物标志物驱动的患者选择方面的进展，也通过展示可衡量的治疗获益，提高了临床试验效率并提升了报销接受度。Digital patient monitoring, remote care support, and specialist pharmacy coordination are becoming increasingly important for long-term treatment success, especially for therapies requiring continuous safety monitoring. 数字化患者监测、远程护理支持以及专业药房协调对于长期治疗的成功日益重要，尤其是对于需要持续安全监测的治疗方案。Analyst Perspective 分析师视角' 'Rare neurological disease treatment is entering a transformative growth phase, driven by earlier genetic diagnosis, accelerating orphan drug approvals, and expanding access to specialist therapies. As precision medicine advances, companies that combine clinical innovation with strong patient access and long-term evidence generation will be best positioned to lead this rapidly evolving market.. 罕见神经系统疾病治疗正进入一个变革性的增长阶段，这得益于更早的基因诊断、孤儿药审批加速以及专科治疗可及性的扩大。随着精准医学的进步，那些将临床创新与强大的患者可及性及长期证据生成相结合的企业，将最有能力引领这个快速演变的市场。' says 说FMI Analyst FMI分析师Anurag Sharma 阿努拉格·夏尔马. 。Market Challenges & Restraints 市场挑战与制约因素Despite strong growth potential, the market faces several structural challenges. 尽管增长潜力强劲，市场仍面临若干结构性挑战。One major barrier is the 一个主要障碍是high cost of therapy development and commercialization 疗法开发与商业化的高昂成本. Rare neurological diseases involve small patient populations, making R&D investment recovery challenging. 罕见的神经系统疾病患者群体规模较小，使得研发投资回收面临挑战。Reimbursement complexity remains another major restraint. Payers increasingly require robust real-world evidence and long-term efficacy data before approving coverage for expensive specialty therapies. 报销复杂性仍然是另一个主要制约因素。在批准覆盖昂贵的专业疗法之前，支付方越来越要求提供有力的真实世界证据和长期疗效数据。Clinical trial limitations also constrain growth. Small patient populations make enrollment difficult and often result in limited long-term comparative data. 临床试验的局限性也制约了增长。患者群体规模小使得入组困难，并常常导致长期对比数据有限。Complex administration requirements for gene therapies, intrathecal drugs, and biologics further increase treatment costs and restrict adoption to specialist centers. 基因疗法、鞘内注射药物和生物制剂的复杂管理要求进一步增加了治疗成本，并使其应用仅限于专业医疗中心。Segment Analysis 细分市场分析The rare neurological disease treatment market is segmented by drug class, indication, route of administration, therapy type, distribution channel, patient type, and region. 罕见神经系统疾病治疗市场按药物类别、适应症、给药途径、治疗类型、分销渠道、患者类型和地区进行细分。By Drug Class 按药物类别Anti-depressants are projected to account for 抗抑郁药预计将占26.0% market share in 2026 2026年市场份额为26.0%, supported by symptom management needs in progressive neurological disorders. ，由进行性神经系统疾病中的症状管理需求所支持。Other major drug classes include: 其他主要药物类别包括：Anticonvulsants 抗惊厥药Immunomodulators 免疫调节剂Nerve Protectors 神经保护剂Muscle Modulators 肌肉调节剂By Indication 按适应症ALS 肌萎缩侧索硬化症is expected to dominate indication demand with 预计将以主导适应症需求30.0% market share in 2026 2026年市场份额为30.0%, driven by disease-modifying therapies and long-term specialist care. ，由疾病修正治疗和长期专科护理驱动。Other key indications include: 其他关键适应症包括：SMA 脊髓性肌萎缩症DMD 杜氏肌营养不良Rare Epilepsies 罕见癫痫NPC 非玩家角色MLD MLDBy Route of Administration 按给药途径Oral therapies remain dominant, accounting for 口服疗法仍占主导地位，占比为72.0% share in 2026 2026年占比72.0%due to convenience and suitability for long-term treatment. 因其便利性且适合长期治疗。Intrathecal and injectable therapies remain critical for advanced gene and CNS-targeted therapies. 鞘内注射和可注射疗法对于先进的基因治疗及中枢神经系统靶向疗法仍然至关重要。By Therapy Type 按治疗类型Small molecules are projected to hold 小分子预计将占据46.0% market share in 2026 2026年市场份额为46.0%, reflecting broad usage across chronic supportive treatments. ，反映了其在慢性支持性治疗中的广泛应用。Gene therapies and antisense therapies continue gaining strategic importance in precision rare-disease treatment. 基因疗法和反义疗法在精准罕见病治疗中持续获得战略重要性。By Distribution Channel 按分销渠道Specialty pharmacies are expected to capture 专业药房预计将占据54.0% market share in 2026 2026年市场份额为54.0%, supported by reimbursement assistance, prior authorization handling, and controlled distribution. ，并由报销援助、事先授权处理以及可控分销提供支持。By Patient Type 按患者类型Adult patients are projected to account for 预计成年患者将占58.0% share in 2026 2026年占比58.0%, driven by long-term therapy use in chronic rare neurological conditions. ，由慢性罕见神经系统疾病的长期治疗使用所驱动。Customize insights for your business strategy: 为您的业务战略定制洞察：https://www.futuremarketinsights.com/customization-available/rep-gb-6445 https://www.futuremarketinsights.com/customization-available/rep-gb-6445Regional Analysis 区域分析Regional growth increasingly depends on diagnostic infrastructure, orphan drug regulation, reimbursement systems, and specialist care access. 区域增长日益依赖于诊断基础设施、孤儿药监管、报销体系以及专科医疗服务的可及性。The 这United States 美国remains the largest market and is expected to grow at 仍然是最大的市场，并预计将以7.8% CAGR through 2036 至2036年的年复合增长率为7.8%, supported by strong orphan drug approvals, specialist neurology centers, and favorable regulatory pathways. ，得益于强劲的孤儿药审批、专业的神经病学中心以及有利的监管途径。China 中国is the fastest-growing major market with 是增长最快的主要市场，8.8% CAGR 8.8% 年均复合增长率, driven by improved rare disease review systems, expanding specialist hospitals, and growing patient identification. ，在罕见病审评体系不断完善、专科医院规模不断扩大以及患者识别率不断提高的推动下。Canada 加拿大is forecast to grow at 预计将以7.2% CAGR 7.2% 年复合增长率, benefiting from federal funding support for rare disease therapies. ，受益于联邦政府对罕见病疗法的资金支持。The 这United Kingdom 英国is projected to expand at 预计将以7.0% CAGR 7.0% 年复合增长率, supported by large-scale genomic testing and structured rare disease care pathways. ，由大规模基因组检测和结构化的罕见病诊疗路径提供支持。Germany 德国and 和France 法国continue to benefit from strong specialist treatment networks and reimbursement frameworks, while 继续受益于强大的专科治疗网络和报销体系，同时Japan 日本maintains stable growth under strict orphan drug regulations. 在严格的孤儿药法规下保持稳定增长。Competitive Landscape 竞争格局Competition is intensifying among specialty neurology companies, gene therapy developers, and orphan drug innovators. 专业神经病学公司、基因疗法开发商和孤儿药创新者之间的竞争正在加剧。Competitive advantage increasingly depends on: 竞争优势越来越依赖于：Clinical evidence strength 临床证据强度Specialist therapy support 专业治疗支持Reimbursement readiness 报销准备情况Distribution channel control 分销渠道控制Long-term safety monitoring 长期安全性监测As therapies become more specialized, companies must provide comprehensive care support beyond drug supply. 随着疗法日益专业化，企业必须在药品供应之外提供全面的护理支持。Leading Companies Analysis 领先企业分析Key market participants include Biogen Inc., Novartis AG, and Sarepta Therapeutics Inc., all of which maintain strong rare neurology portfolios and specialist treatment expertise. 主要市场参与者包括渤健公司（Biogen Inc.）、诺华公司（Novartis AG）和萨雷普塔治疗公司（Sarepta Therapeutics Inc.），这些公司均拥有强大的罕见神经疾病产品组合和专科治疗专长。Other important participants include: 其他重要参与者包括：PTC Therapeutics Inc. PTC 治疗公司Ionis Pharmaceuticals Inc. Ionis 制药公司Zevra Therapeutics Inc. Zevra Therapeutics 公司IntraBio Inc. IntraBio 公司Investment & Strategic Developments 投资与战略发展Investment activity is accelerating in gene therapy manufacturing, orphan drug development, and specialist treatment infrastructure. 基因疗法生产、孤儿药开发以及专科治疗基础设施领域的投资活动正在加速。Strategic partnerships between therapy developers, specialty pharmacies, and healthcare providers are becoming critical to ensure successful commercialization. 疗法开发商、专业药房和医疗保健提供者之间的战略合作伙伴关系对于确保成功的商业化变得至关重要。Long-term investment is increasingly focused on improving treatment accessibility, evidence generation, and post-approval patient monitoring. 长期投资正日益聚焦于提升治疗可及性、生成证据以及开展获批后患者监测。Investors are paying close attention to reimbursement decisions, orphan exclusivity, and regulatory flexibility, as these factors strongly influence long-term commercial returns. 投资者正密切关注报销决策、孤儿药独占权以及监管灵活性，因为这些因素对长期商业回报具有重大影响。Future Outlook 未来展望The rare neurological disease treatment market is expected to become increasingly specialized over the next decade. 预计在未来十年，罕见神经系统疾病治疗市场将日益专业化。Future growth will be shaped by: 未来增长将受到以下因素的影响：Expansion of orphan drug approvals 孤儿药批准的扩展Earlier genetic diagnosis 早期基因诊断Growth of gene therapies 基因疗法的增长Improved reimbursement frameworks 改进的报销框架Stronger specialist care networks 更强大的专科护理网络The industry is likely to continue shifting toward precision therapeutics with measurable disease-modifying outcomes. 该行业可能会继续向具有可衡量的疾病修饰结果的精准治疗方向转变。Conclusion 结论The rare neurological disease treatment market is transitioning from a niche orphan segment into a high-value strategic pharmaceutical category. With the market projected to grow from 罕见神经系统疾病治疗市场正从一个利基孤儿药细分领域转变为高价值的战略制药类别。随着市场预计从USD 21.5 billion in 2026 to USD 43.7 billion by 2036 从2026年的215亿美元增长到2036年的437亿美元, long-term growth remains strong. 长期增长依然强劲。Demand is increasingly tied to early diagnosis, targeted therapies, and specialist care rather than conventional symptom management. Companies capable of combining scientific innovation with strong access and monitoring infrastructure will be best positioned to lead the next phase of market growth. 需求正日益与早期诊断、靶向治疗和专科护理挂钩，而非传统的症状管理。能够将科学创新与强大的可及性和监测基础设施相结合的公司，将在下一阶段的市场增长中占据最有利的领先地位。Explore the Latest Healthcare Industry Analysis Now: 立即探索最新的医疗健康行业分析：https://www.futuremarketinsights.com/industry-analysis/healthcare https://www.futuremarketinsights.com/industry-analysis/healthcareExplore Industry Insights: 探索行业洞察：https://www.futuremarketinsights.com/industry-analysis https://www.futuremarketinsights.com/industry-analysisFMI Custom Research: Strategic Intelligence for Confident Decision-Making FMI定制研究：助力自信决策的战略情报In today's rapidly evolving business environment, leadership teams need more than market data—they need clear, actionable intelligence tailored to their strategic objectives. FMI's Custom Research solutions are designed around the specific business questions organizations need answered, enabling executives to evaluate growth opportunities, validate investments, assess competitive dynamics, and reduce uncertainty before making critical decisions. 在当今快速变化的商业环境中，领导团队需要的不仅仅是市场数据，他们还需要针对其战略目标量身定制的清晰、可操作的洞察。FMI 的定制研究解决方案围绕企业需要解答的具体业务问题而设计，帮助高管在做出关键决策之前评估增长机会、验证投资决策、分析竞争格局并降低不确定性。By combining deep industry expertise, primary research, and proprietary market intelligence, FMI delivers insights that help organizations move from assumptions to evidence-based strategies with greater speed and confidence.. FMI 通过结合深厚的行业专业知识、一手研究和专有市场情报，提供有助于组织更快速、更自信地从假设转向基于证据的战略的洞察。Key Executive Benefits 关键高管福利Decision-Ready Insights: 可辅助决策的洞察：Research tailored to your specific business challenges, growth plans, and investment priorities. 根据您的具体业务挑战、增长计划和投资重点量身定制的研究。Reduced Strategic Risk: 降低战略风险：Validate market opportunities, customer demand, and competitive positioning before committing resources. 在投入资源之前，验证市场机会、客户需求和竞争定位。Market Entry Confidence: 市场进入信心：Assess opportunity size, regulatory barriers, channel dynamics, and competitive landscapes with precision. 精准评估市场机会规模、监管壁垒、渠道动态及竞争格局。Competitive Advantage: 竞争优势：Gain proprietary intelligence unavailable through syndicated reports or internal datasets. 获取通过联合报告或内部数据集无法获得的专有情报。Faster Growth Decisions: 更快的增长决策：Accelerate expansion, product development, portfolio optimization, and investment planning. 加速扩张、产品开发、产品组合优化和投资规划。Primary Market Validation: 一级市场验证：Access real-world customer, buyer, and stakeholder insights that support high-confidence decision-making. 获取真实的客户、买家和利益相关者洞察，支持高置信度的决策。Global Industry Expertise: 全球行业专长：Powered by 100+ analysts, 20,000+ published reports, and 1.6 million+ hours of research experience. 由100多位分析师、20,000多份已发布报告以及160多万小时的研究经验提供支持。Proven Track Record: 业绩卓著：Over 7,000 market-entry engagements completed across six regions and 14 industry sectors with strong client retention. 在六个地区和十四个行业领域完成了超过7,000次市场进入项目，客户留存率强劲。Business Impact 业务影响FMI helps organizations transform market complexity into strategic clarity, enabling leadership teams to identify growth opportunities faster, optimize resource allocation, strengthen competitive positioning, and make high-stakes business decisions with confidence. FMI帮助组织将市场复杂性转化为战略清晰度，使领导团队能够更快地识别增长机会、优化资源配置、强化竞争定位，并自信地做出高风险业务决策。To explore how FMI Custom Research can support your strategic priorities, please connect with our team at - 如需了解 FMI 定制研究如何支持您的战略重点，请联系我们的团队：[emailprotected] [email protected]Related Reports: 相关报告：Rare Disease Clinical Trials Market - 罕见病临床试验市场 -https://www.futuremarketinsights.com/reports/rare-disease-clinical-trials-market https://www.futuremarketinsights.com/reports/rare-disease-clinical-trials-marketInflammatory Bowel Disease Treatment Market - 炎症性肠病治疗市场 -https://www.futuremarketinsights.com/reports/inflammatory-bowel-disease-treatment-market https://www.futuremarketinsights.com/reports/inflammatory-bowel-disease-treatment-marketNeglected Tropical Disease Treatment Market - 被忽视的热带病治疗市场 -https://www.futuremarketinsights.com/reports/neglected-tropical-disease-treatment-market https://www.futuremarketinsights.com/reports/neglected-tropical-disease-treatment-marketAutosomal Dominant Polycystic Kidney Disease Treatment Market - 常染色体显性多囊肾病治疗市场 -https://www.futuremarketinsights.com/reports/autosomal-dominant-polycystic-kidney-disease-market https://www.futuremarketinsights.com/reports/autosomal-dominant-polycystic-kidney-disease-marketDemand for Autosomal Dominant Polycystic Kidney Disease Treatment in USA - 美国常染色体显性多囊肾病治疗需求 -https://www.futuremarketinsights.com/reports/united-states-autosomal-dominant-polycystic-kidney-disease-treatment-market https://www.futuremarketinsights.com/reports/united-states-autosomal-dominant-polycystic-kidney-disease-treatment-marketAbout Future Market Insights (FMI) 关于未来市场洞察（FMI）Future Market Insights (FMI) delivers actionable, decision-focused market intelligence that goes beyond traditional research reports. The company provides: 未来市场洞察（FMI）提供可操作的、以决策为重点的市场情报，超越传统研究报告。该公司提供：In-depth pricing and cost benchmarking analysis 深度定价与成本基准分析Demand forecasting based on real industry inputs 基于真实行业输入的需求预测Procurement and buyer behavior insights 采购与买家行为洞察Supply chain and trade flow intelligence 供应链与贸易流情报Technology and application trend analysis across industries 跨行业的技术与应用趋势分析FMI follows a robust bottom-up researchmethodology, combining insights from industry experts, procurement leaders, manufacturers, and technical professionals to ensureaccurateand practical market intelligence. FMI 采用稳健的自下而上研究方法，融合行业专家、采购负责人、制造商和技术专业人士的见解，以确保市场情报的准确性和实用性。For Press & Corporate Inquiries 媒体及企业咨询Rahul Singh 拉胡尔·辛格AVP - Marketing and Growth Strategy 助理副总裁 - 市场营销与增长战略Future Market Insights, Inc. 未来市场洞察公司+91 8600020075 +91 8600020075For Media 媒体- -[emailprotected] [email protected]For web 适用于网页版- -https://www.futuremarketinsights.com/ https://www.futuremarketinsights.com/Logo - 标志 -https://mma.prnewswire.com/media/1197648/6013216/FMI_Logo.jpg https://mma.prnewswire.com/media/1197648/6013216/FMI_Logo.jpgSOURCE Future Market Insights 来源：未来市场洞察21 二十一% %more press release views with 更多新闻稿浏览量，借助Request a Demo 申请演示